Available on demand. The demonstration of similar immunogenicity is a critical requirement for the demonstration of similarity between a biosimilar candidate and the respective reference product.
Find out more about the co-development agreement between Xbrane and STADA for a ranibizumab biosimilar, and about a novel biomarker test for establishing lung cancer risk in smokers in this week’s bioanalytical news round-up.
View webinar on demand
How we can use the Xevo Mass Spectrometer, combined with immunoaffinity extraction to provide a premium sensitivity assay for our clients and help them drive forward the development of insulin molecules and their biosimilars?
The first biosimilar for the treatment of breast and stomach cancers has been approved by the FDA, termed Ogivri.
2. Given the complexity and cost of development and manufacturing, are biosimilars more affordable therapeutic options?
In this ‘Ask the Experts’ feature, the experts discuss the complexity and cost of development and whether biosimilars are more affordable therapeutic options.
In this ‘Ask the Experts’ feature we will be discussing the use of biosimilars with a number of leading experts across the field. The series will explore the role of biosimilars, address the benefits and challenges of creating them and how they have gained momentum within the pharmaceutical industry.
Amgen and Simcere announce collaboration in the development and distribution of biosimilars in China
An exclusive agreement between Amgen and Simcere has been announced in the co-development and commercialization of four undisclosed oncology and inflammation biosimilars.
In this feature we ask the question: how can the biosimilars field be regulated and standardized?
We asked our experts: what have been the most exciting advances in developing biosimilars?
WHO have announced plans to include biosimilars for cancer treatments as part of their current prequalifying scheme, in the hope to make treatment more available in low income countries.